Generic Name: upadacitinib
Brand Name: Rinvoq
Therapeutic Area: atopic dermatitis
Indications: RINVOQ is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. RINVOQ can be used with or without topical corticosteroids.
Manufacturer Requested Reimbursement Criteria1: For the treatment of patients aged 12 years and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and/or who are refractory to or ineligible for systemic immunosuppressant therapies (i.e., due to contraindications, intolerance, or need for long-term treatment).
Submission Type: Initial
NOC Status at Filing: Pre NOC
Project Status: Active
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||March 15, 2021|
|Call for patient/clinician input closed||May 07, 2021|
- Patient input submission received from the Canadian Skin Patient Alliance (CSPA) & Eczéma Québec and the Eczema Society of Canada
|Submission received||April 13, 2021|
|Submission accepted||April 27, 2021|
|Review initiated||April 28, 2021|
|Draft CADTH review report(s) provided to sponsor for comment||July 20, 2021|
|Deadline for sponsors comments||July 29, 2021|
|CADTH responses on draft review report(s) provided to sponsor||September 10, 2021|
|Expert committee meeting (initial)||September 22, 2021|
|Draft recommendation issued to sponsor||October 04, 2021
October 06, 2021
|Draft recommendation posted for stakeholder feedback||-|